Compare LSTA & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSTA | BCTX |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | Canada |
| Employees | N/A | 4 |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.9M | 26.6M |
| IPO Year | 2000 | 2025 |
| Metric | LSTA | BCTX |
|---|---|---|
| Price | $1.67 | $3.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $15.00 | ★ $40.00 |
| AVG Volume (30 Days) | 65.8K | ★ 163.1K |
| Earning Date | 05-11-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,283,868.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $1.81 | $0.61 |
| 52 Week High | $5.07 | $14.68 |
| Indicator | LSTA | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 19.52 | 50.05 |
| Support Level | N/A | $2.98 |
| Resistance Level | $2.19 | $4.51 |
| Average True Range (ATR) | 0.22 | 0.26 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 1.40 | 25.81 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.